Chronic kidney disease (CKD) is a commonly diagnosed condition, affecting approximately 30 million adults in the United States.1 CKD refers to a diverse group of pathologies that result in kidney function decline for at least 3 months.2,3 Kidney disease etiologies are generally classified into 3 categories: prerenal, intrinsic renal, and postrenal. Prerenal disease is marked…
A small study of patients with metastatic renal cell carcinoma and bone metastases found a trend toward better survival among patients treated with TKIs plus bone-targeted therapies vs those treated with TKIs alone.
Axitinib plus pembrolizumab is recommended as first-line therapy for patients with favorable-risk clear cell advanced renal cell carcinoma, according to an updated position statement from the Society for Immunotherapy of Cancer.
Patients receiving modern immunotherapy for metastatic renal cell carcinoma have a decreased risk of death if they also undergo cytoreductive nephrectomy, a study found.
